Fentanyl Shortage Creates a Painful Situation - LGM Pharma Blog
As a rapid acting pain medication, Fentanyl is an efficacious and tolerable treatment for moderate to severe pain. The news on August 26, 2013 of a continued shortage of this pain relieving remedy has created concern among the medical community. Emergency medical services are proponents of the use of Fentanyl over morphine for pain, as are many hospital and surgical centers. With a 30 minute wait for total pain relief, Fentanyl outperforms Morphine, which often takes up to 4 hours for patients to experience cessation of pain. Besides being a shorter-acting pain reliever, Fentanyl does not usually induce hypotension, unlike morphine. Patients who have been administered Fentanyl for pain report on average less adverse effects like nausea and vomiting in comparison to patients who have been administered morphine. Additionally, the use of Fentanyl in a pre-hospital or emergency services setting has proven to be safe and effectual for patients, as the administration of this pain relieving drug does not tend to cause respiratory depression or distress, sedation or hypoxemia. With all of the benefits of Fentanyl it is obvious that the current shortage of this crucial pain treatment will make caring for patients afflicted with pain quite a challenge.
Fentanyl is effective as it acts mainly via an interaction with the opioid mu receptors in the brain. This interaction creates both analgesia and euphoria, without the plethora of adverse side effects of comparable medications such as morphine. The use of Fentanyl is recommended for patients suffering from moderate to severe pain, including burn victims. Several brands of Fentanyl are nearing patent expiration as well. On April 20, 2018 Lazanda will reach its patent expiration. Abstral has a patent expiration of September 24, 2019 and Fentora will see the end of its patent on March 26, 2019.
If you are in the pharmaceutical industry, and you are concerned about your ability to acquire Fentanyl from a reputable source, LGM Pharma can assist you with your needs. LGM Pharma provides the Fentanyl CAS# 437-38-7 API for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
Tags: 437-38-7, Abstral, Fentanyl, Fentanyl outperforms Morphine, Fentanyl over morphine, Fentora, hypotension, Lazanda
This entry was posted on Friday, October 4th, 2013 at 3:13 pm and is filed under Anesthetic, FDA Drug Shortage, Patent Expiration 2018, Patent Expiration 2019, Therapeutic Classification. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.